Industry To FDA: Realign Incentives For Rx Drugs To Spur CBD Research

The pharmaceutical industry, including GW Pharmaceuticals, the producer of cannabidiol-containing drug Epidiolex, warns FDA that allowing CBD in consumer products could freeze research and development on use of CBD in prescription drugs. The agency could remedy this, GW argues, by crafting policies that encourage expansion of medical research on cannabis and its derivatives while simultaneously allowing controlled marketing of CBD in foods and dietary supplements. FDA could incentivize continued investment in the prescription drug space through drug development programs that...